Sarah Scatigna

- Support strategic initiatives in Sales & Marketing for different business lines. - Enhance operational efficiency and cross-functional collaboration, ensuring alignment with corporate objectives while optimizing execution across teams - Manage senior stakeholders and tracked key deliverables, identifying areas for continuous improvement

Conducted research within the Marie Curie-funded EDUC8 consortium, collaborating with international scientists to develop CAR-Tregs for immune tolerance induction in Hemophilia A patients. - Focused on Cell Therapy, Immunology, Blood disorders, Hemophilia, Genetic Engineering - Engineered and tested multiple CARs in T-cells, performing extensive functional in vitro and ex vivo validation to identify the most beneficial for Tregs. - Managed laboratory operations, research budgets, and student supervision

A research study on immune tolerance induction through chimeric antigen receptor (CAR) transduced T regulatory cells (Tregs). - Cell therapy, protein immunogenicity, coagulation disorders - Coordinated research activities, collaborating with team members, managing financial activities and resource planning - Member of the international European consortium “EDUC8” which comprises leading scientists who collaborate with the shared goal of understanding the immunogenicity of Hemophilia A biotherapeutics

Design of a clinical development plan for a new Hemophilia A drug in compliance with EMA and FDA guidelines strictly adhering to project timelines and quality standards. - Designed pre-clinical and clinical studies, focusing on pharmacokinetic and pharmacodynamic (PK/PD) analysis - Worked on manufacturing practices and product specifications involved in the chemistry, manufacturing and control (CMC) section, selecting and validating analytical methods to ensure accurate and reliable testing processes

Research study on oncolytic herpes simplex viruses (HSV-1) specifically retargeted to receptors expressed on cancer cells, acting as potential in situ tumor vaccines. - Focused on cancer immunology and oncolytic virotherapy - Conducted in-vitro characterization of herpetic oncolytic viruses - Supervised and trained students throughout the project, fostering a positive and collaborative learning environment

Selective, fully funded program (3% admission rate) focused on strategy, innovation, and leadership.